Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
It’s been a rough 2019 for some biotechs. Amneal Pharmaceuticals Inc (NYSE:AMRX) is down 81% year-to-date, while Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is down 41%.
JPMorgan sees redemption in one of the stocks — and further decline in the other.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Analyst
Chris Schott upgraded Teva from Underweight to Neutral with an $8 price target and downgraded Amneal from Neutral to Underweight.
The Teva Thesis
With positive optics on Teva’s opioid exposure and stabilizing mid-term fundamentals, JPMorgan sees balance in the stock’s costs and benefits.
“We remain fairly bearish on the longer-term setup for the company between its lack of growth-drivers (Ajovy underperforming expectations so far, lingering LOEs, etc.) and still high-leverage (especially after taking into account potential cash flow going to opioids),” Schott said in a Tuesday note. (See his track record here.)
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
The Amneal Thesis
Amneal offers little opportunity for redemption, the analyst said.
After a series of poor earnings and lower guidance, the company’s turnaround depends on an unlikely pipeline success, according to JPMorgan.
“While some of the challenges facing Amneal do appear fixable (supply penalties, plant utilization, etc.), many appear fundamental (a function of the evolving dynamics in the US Gx market), and will likely take time and resources to fix (which the company is increasingly lacking at 7x leverage and with an ever-depressed equity value),” Schott said.
Price Action
Teva shares were trading 1.93% higher at $9.51 at the time of publication Tuesday, while Amneal shares were up 4.36% at $2.76.
Related Links:
4 Pharma Companies Settle Opioid Lawsuits Ahead Of Trial With Ohio Counties; 2,300 Cases Remain
Opioid Drug Companies Rally On Hopes of Broader Settlement
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.